Insulet Corp. (PODD)
Insulet Corp. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Acton, MA, US. The stock last traded at $146.87, down 3.06% on the session, giving a market capitalisation of $10.17B. On trailing twelve-month figures it carries a trailing P/E of 27.40, a net margin of 12.3%. Its beta of 1.09 implies it has historically moved more than the broad market.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corp. is most often compared with the following Healthcare names: